fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Tacrolimus

Form:

23 of 23 products shown

All products: Limited Use (codes 173, 383, 410, 590)

Protopic · DIN 02244149 · 0.03% · Oint

Limited Use, Reason for Use code 383 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 383 required
Write on scriptReason for Use code 383 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 383
Reason for Use code 383 For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid. Coverage limit: Therapy should be reassessed at 6 months. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Protopic · DIN 02244149 Manufacturer: Leo Pharma Inc.; listing date 2004-04-06 Health Canada: Marketed since 2017-05-25 · brand PROTOPIC · ATC D11AH01 TACROLIMUS · form Ointment · route Topical · ingredients TACROLIMUS 0.03 %/W/W · company Leo pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Protopic: Formulary list price $3.43 per unit (the source does not state the unit; exact figure $3.4301). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244149)

Source record
DIN 02244149: Protopic Raw flags: sec12=Y, sec3=Y Item: 920000411; group id 968; item number 2299; lccId 00153; manufacturer id LEO Source form: Oint; strength: 0.03% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.4301; ministry $3.4301 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244149 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68110
Shortage status: discontinued (April 15, 2025, reported by LEO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244149
Shortage record checked October 6, 2026

Protopic · DIN 02244148 · 0.1% · Oint

Limited Use, Reason for Use code 383 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 383 required
Write on scriptReason for Use code 383 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 383
Reason for Use code 383 For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid. Coverage limit: Therapy should be reassessed at 6 months. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Protopic · DIN 02244148 Manufacturer: Leo Pharma Inc.; listing date 2004-04-06 Health Canada: Marketed since 2017-05-25 · brand PROTOPIC · ATC D11AH01 TACROLIMUS · form Ointment · route Topical · ingredients TACROLIMUS 0.1 %/W/W · company Leo pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Protopic: Formulary list price $3.67 per unit (the source does not state the unit; exact figure $3.6691). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244148)

Source record
DIN 02244148: Protopic Raw flags: sec12=Y, sec3=Y Item: 920000402; group id 968; item number 2300; lccId 00153; manufacturer id LEO Source form: Oint; strength: 0.1% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.6691; ministry $3.6691 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244148 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68109
Shortage status: discontinued (April 15, 2025, reported by LEO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244148
Shortage record checked October 6, 2026

Ach-Tacrolimus · DIN 02454068 · 0.5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Tacrolimus · DIN 02454068 Manufacturer: Accord Healthcare Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-09-21 · brand ACH-TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS 0.5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ach-Tacrolimus: Formulary list price $1.01 per unit (the source does not state the unit; exact figure $1.0146). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02454068)

Source record
DIN 02454068: Ach-Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000391; group id 966; item number 2292; lccId 00137; manufacturer id ACH Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0146; ministry $1.0146 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02454068 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94058
Interchangeable products
Prograf · DIN 02243144 · $1.0146 Sandoz Tacrolimus · DIN 02416816 · $1.0146
Shortage status: resolved shortage (ended July 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02454068
Shortage record checked October 6, 2026

Prograf · DIN 02243144 · 0.5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Prograf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Prograf · DIN 02243144 Manufacturer: Astellas Pharma Canada Inc.; listing date 2009-04-01 Health Canada: Marketed since 2005-11-07 · brand PROGRAF · ATC L04AD02 TACROLIMUS · form Capsule · route Oral · ingredients TACROLIMUS 0.5 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243144)

Source record
DIN 02243144: Prograf Raw flags: sec12=Y, sec3=Y Item: 920000391; group id 966; item number 2292; lccId 00137; manufacturer id ASE Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0291; ministry $1.0146 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243144 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67015
Interchangeable products
Ach-Tacrolimus · DIN 02454068 · $1.0146 Sandoz Tacrolimus · DIN 02416816 · $1.0146
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243144
Shortage record checked October 6, 2026

Sandoz Tacrolimus · DIN 02416816 · 0.5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Tacrolimus · DIN 02416816 Manufacturer: Sandoz Canada Inc.; listing date 2015-01-28 Health Canada: Marketed since 2014-06-11 · brand SANDOZ TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS (TACROLIMUS MONOHYDRATE) 0.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus: Formulary list price $1.01 per unit (the source does not state the unit; exact figure $1.0146). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416816)

Source record
DIN 02416816: Sandoz Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000391; group id 966; item number 2292; lccId 00137; manufacturer id SDZ Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0146; ministry $1.0146 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416816 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90142
Interchangeable products
Ach-Tacrolimus · DIN 02454068 · $1.0146 Prograf · DIN 02243144 · $1.0146
Shortage status: resolved shortage (ended October 30, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416816
Shortage record checked October 6, 2026

Advagraf · DIN 02296462 · 0.5 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advagraf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advagraf · DIN 02296462 Manufacturer: Astellas Pharma Canada Inc.; listing date 2009-04-01 Health Canada: Marketed since 2008-04-09 · brand ADVAGRAF · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 0.5 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02296462)

Source record
DIN 02296462: Advagraf Raw flags: sec12=Y, sec3=Y Item: 920000591; group id 967; item number 2295; lccId 00200; manufacturer id ASE Source form: ER Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.2199; ministry $1.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296462 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78179
Interchangeable products
Sandoz Tacrolimus XR · DIN 02528592 · $1.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296462
Shortage record checked October 6, 2026

Sandoz Tacrolimus XR · DIN 02528592 · 0.5 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Tacrolimus XR · DIN 02528592 Manufacturer: Sandoz Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2026-04-20 · brand SANDOZ TACROLIMUS XR · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 0.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus XR: Formulary list price $1.22 per unit (the source does not state the unit; exact figure $1.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528592)

Source record
DIN 02528592: Sandoz Tacrolimus XR Raw flags: sec12=Y, sec3=Y Item: 920000591; group id 967; item number 2295; lccId 00200; manufacturer id SDZ Source form: ER Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.2209; ministry $1.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528592 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101780
Interchangeable products
Advagraf · DIN 02296462 · $1.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528592
Shortage record checked October 6, 2026

Envarsus PA · DIN 02485877 · 0.75 mg · extended release tablet

Limited Use, Reason for Use code 590 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 590 required
Write on scriptReason for Use code 590 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 590
Reason for Use code 590 For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Envarsus PA · DIN 02485877 Manufacturer: Endo Ventures Ltd.; listing date 2020-09-30 Health Canada: Marketed since 2026-03-23 · brand ENVARSUS PA · ATC L04AD02 TACROLIMUS · form Tablet (extended-release) · route Oral · ingredients TACROLIMUS 0.75 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Envarsus PA: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0999). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02485877)

Source record
DIN 02485877: Envarsus PA Raw flags: sec12=Y, sec3=Y Item: 924400008; group id 1051; item number 2407; lccId 00340; manufacturer id EVL Source form: ER Tab; strength: 0.75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0999; ministry $2.0999 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485877 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97609
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485877
Shortage record checked October 6, 2026

Ach-Tacrolimus · DIN 02456095 · 1 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Tacrolimus · DIN 02456095 Manufacturer: Accord Healthcare Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-09-15 · brand ACH-TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS 1 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ach-Tacrolimus: Formulary list price $1.30 per unit (the source does not state the unit; exact figure $1.2978). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456095)

Source record
DIN 02456095: Ach-Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000221; group id 966; item number 2293; lccId 00137; manufacturer id ACH Source form: Cap; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.2978; ministry $1.2978 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456095 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94294
Interchangeable products
Prograf · DIN 02175991 · $1.2978 Sandoz Tacrolimus · DIN 02416824 · $1.2978
Shortage status: resolved shortage (ended July 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456095
Shortage record checked October 6, 2026

Prograf · DIN 02175991 · 1 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Prograf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Prograf · DIN 02175991 Manufacturer: Astellas Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2006-04-03 · brand PROGRAF · ATC L04AD02 TACROLIMUS · form Capsule · route Oral · ingredients TACROLIMUS 1 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02175991)

Source record
DIN 02175991: Prograf Raw flags: sec12=Y, sec3=Y Item: 920000221; group id 966; item number 2293; lccId 00137; manufacturer id ASE Source form: Cap; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5956; ministry $1.2978 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02175991 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44211
Interchangeable products
Ach-Tacrolimus · DIN 02456095 · $1.2978 Sandoz Tacrolimus · DIN 02416824 · $1.2978
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02175991
Shortage record checked October 6, 2026

Sandoz Tacrolimus · DIN 02416824 · 1 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Tacrolimus · DIN 02416824 Manufacturer: Sandoz Canada Inc.; listing date 2014-01-30 Health Canada: Marketed since 2013-11-25 · brand SANDOZ TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS (TACROLIMUS MONOHYDRATE) 1 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus: Formulary list price $1.30 per unit (the source does not state the unit; exact figure $1.2978). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416824)

Source record
DIN 02416824: Sandoz Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000221; group id 966; item number 2293; lccId 00137; manufacturer id SDZ Source form: Cap; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.2978; ministry $1.2978 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416824 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90143
Interchangeable products
Ach-Tacrolimus · DIN 02456095 · $1.2978 Prograf · DIN 02175991 · $1.2978
Shortage status: resolved shortage (ended November 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416824
Shortage record checked October 6, 2026

Advagraf · DIN 02296470 · 1 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advagraf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advagraf · DIN 02296470 Manufacturer: Astellas Pharma Canada Inc.; listing date 2009-04-01 Health Canada: Marketed since 2008-04-09 · brand ADVAGRAF · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 1 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02296470)

Source record
DIN 02296470: Advagraf Raw flags: sec12=Y, sec3=Y Item: 920000592; group id 967; item number 2296; lccId 00200; manufacturer id ASE Source form: ER Cap; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.8396; ministry $1.5618 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296470 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78180
Interchangeable products
Sandoz Tacrolimus XR · DIN 02528606 · $1.5618
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296470
Shortage record checked October 6, 2026

Sandoz Tacrolimus XR · DIN 02528606 · 1 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Tacrolimus XR · DIN 02528606 Manufacturer: Sandoz Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-11-25 · brand SANDOZ TACROLIMUS XR · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 1 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus XR: Formulary list price $1.56 per unit (the source does not state the unit; exact figure $1.5618). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528606)

Source record
DIN 02528606: Sandoz Tacrolimus XR Raw flags: sec12=Y, sec3=Y Item: 920000592; group id 967; item number 2296; lccId 00200; manufacturer id SDZ Source form: ER Cap; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.5618; ministry $1.5618 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528606 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101781
Interchangeable products
Advagraf · DIN 02296470 · $1.5618
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528606
Shortage record checked October 6, 2026

Envarsus PA · DIN 02485885 · 1 mg · extended release tablet

Limited Use, Reason for Use code 590 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 590 required
Write on scriptReason for Use code 590 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 590
Reason for Use code 590 For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Envarsus PA · DIN 02485885 Manufacturer: Endo Ventures Ltd.; listing date 2020-09-30 Health Canada: Marketed since 2026-03-23 · brand ENVARSUS PA · ATC L04AD02 TACROLIMUS · form Tablet (extended-release) · route Oral · ingredients TACROLIMUS 1 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Envarsus PA: Formulary list price $2.74 per unit (the source does not state the unit; exact figure $2.7430). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02485885)

Source record
DIN 02485885: Envarsus PA Raw flags: sec12=Y, sec3=Y Item: 924400009; group id 1051; item number 2408; lccId 00340; manufacturer id EVL Source form: ER Tab; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.7430; ministry $2.7430 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485885 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97610
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485885
Shortage record checked October 6, 2026

Advagraf · DIN 02331667 · 3 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advagraf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advagraf · DIN 02331667 Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-03-15 Health Canada: Marketed since 2010-04-05 · brand ADVAGRAF · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 3 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02331667)

Source record
DIN 02331667: Advagraf Raw flags: sec12=Y, sec3=Y Item: 920000621; group id 967; item number 2297; lccId 00200; manufacturer id ASE Source form: ER Cap; strength: 3mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $8.5188; ministry $4.6853 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02331667 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81736
Interchangeable products
Sandoz Tacrolimus XR · DIN 02528622 · $4.6853
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02331667
Shortage record checked October 6, 2026

Sandoz Tacrolimus XR · DIN 02528622 · 3 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Tacrolimus XR · DIN 02528622 Manufacturer: Sandoz Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-11-25 · brand SANDOZ TACROLIMUS XR · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 3 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus XR: Formulary list price $4.69 per unit (the source does not state the unit; exact figure $4.6853). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528622)

Source record
DIN 02528622: Sandoz Tacrolimus XR Raw flags: sec12=Y, sec3=Y Item: 920000621; group id 967; item number 2297; lccId 00200; manufacturer id SDZ Source form: ER Cap; strength: 3mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.6853; ministry $4.6853 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528622 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101783
Interchangeable products
Advagraf · DIN 02331667 · $4.6853
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528622
Shortage record checked October 6, 2026

Envarsus PA · DIN 02485893 · 4 mg · extended release tablet

Limited Use, Reason for Use code 590 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 590 required
Write on scriptReason for Use code 590 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 590
Reason for Use code 590 For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Envarsus PA · DIN 02485893 Manufacturer: Endo Ventures Ltd.; listing date 2020-09-30 Health Canada: Marketed since 2026-03-23 · brand ENVARSUS PA · ATC L04AD02 TACROLIMUS · form Tablet (extended-release) · route Oral · ingredients TACROLIMUS 4 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Envarsus PA: Formulary list price $10.97 per unit (the source does not state the unit; exact figure $10.9719). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02485893)

Source record
DIN 02485893: Envarsus PA Raw flags: sec12=Y, sec3=Y Item: 924400010; group id 1051; item number 2409; lccId 00340; manufacturer id EVL Source form: ER Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $10.9719; ministry $10.9719 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485893 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97611
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485893
Shortage record checked October 6, 2026

Prograf · DIN 02176009 · 5 mg/mL · Amp

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Prograf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
No interchangeable product listed in the Ontario extract
Prograf · DIN 02176009 Manufacturer: Astellas Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2005-09-15 · brand PROGRAF · ATC L04AD02 TACROLIMUS · form Solution · route Intravenous · ingredients TACROLIMUS 5 MG/ML · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Prograf: Formulary list price $128.24 per unit (the source does not state the unit; exact figure $128.2350). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02176009)

Source record
DIN 02176009: Prograf Raw flags: sec12=Y, sec3=Y Item: 920000224; group id 966; item number 2291; lccId 00137; manufacturer id ASE Source form: Amp; strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $128.2350; ministry $128.2350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02176009 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44212
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02176009
Shortage record checked October 6, 2026

Ach-Tacrolimus · DIN 02456109 · 5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Tacrolimus · DIN 02456109 Manufacturer: Accord Healthcare Inc.; listing date 2023-11-30 Health Canada: Marketed since 2023-09-15 · brand ACH-TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS 5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ach-Tacrolimus: Formulary list price $6.50 per unit (the source does not state the unit; exact figure $6.4993). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02456109)

Source record
DIN 02456109: Ach-Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000222; group id 966; item number 2294; lccId 00137; manufacturer id ACH Source form: Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.4993; ministry $6.4993 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02456109 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94295
Interchangeable products
Prograf · DIN 02175983 · $6.4993 Sandoz Tacrolimus · DIN 02416832 · $6.4993
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456109
Shortage record checked October 6, 2026

Prograf · DIN 02175983 · 5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Prograf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Prograf · DIN 02175983 Manufacturer: Astellas Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2006-04-03 · brand PROGRAF · ATC L04AD02 TACROLIMUS · form Capsule · route Oral · ingredients TACROLIMUS 5 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02175983)

Source record
DIN 02175983: Prograf Raw flags: sec12=Y, sec3=Y Item: 920000222; group id 966; item number 2294; lccId 00137; manufacturer id ASE Source form: Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $12.9986; ministry $6.4993 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02175983 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44210
Interchangeable products
Ach-Tacrolimus · DIN 02456109 · $6.4993 Sandoz Tacrolimus · DIN 02416832 · $6.4993
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02175983
Shortage record checked October 6, 2026

Sandoz Tacrolimus · DIN 02416832 · 5 mg · capsule

Limited Use, Reason for Use code 173 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 173 required
Write on scriptReason for Use code 173 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 173
Reason for Use code 173 For solid organ transplant and bone marrow transplant. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Tacrolimus · DIN 02416832 Manufacturer: Sandoz Canada Inc.; listing date 2014-01-30 Health Canada: Marketed since 2013-11-25 · brand SANDOZ TACROLIMUS · ATC L04AD02 TACROLIMUS · form Capsule (immediate-release) · route Oral · ingredients TACROLIMUS (TACROLIMUS MONOHYDRATE) 5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus: Formulary list price $6.50 per unit (the source does not state the unit; exact figure $6.4993). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416832)

Source record
DIN 02416832: Sandoz Tacrolimus Raw flags: sec12=Y, sec3=Y Item: 920000222; group id 966; item number 2294; lccId 00137; manufacturer id SDZ Source form: Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.4993; ministry $6.4993 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416832 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90144
Interchangeable products
Ach-Tacrolimus · DIN 02456109 · $6.4993 Prograf · DIN 02175983 · $6.4993
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416832
Shortage record checked October 6, 2026

Advagraf · DIN 02296489 · 5 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advagraf (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advagraf · DIN 02296489 Manufacturer: Astellas Pharma Canada Inc.; listing date 2009-04-01 Health Canada: Marketed since 2008-04-09 · brand ADVAGRAF · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 5 MG · company Astellas pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02296489)

Source record
DIN 02296489: Advagraf Raw flags: sec12=Y, sec3=Y Item: 920000593; group id 967; item number 2298; lccId 00200; manufacturer id ASE Source form: ER Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $14.2205; ministry $7.8213 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296489 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78181
Interchangeable products
Sandoz Tacrolimus XR · DIN 02528630 · $7.8213
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02296489
Shortage record checked October 6, 2026

Sandoz Tacrolimus XR · DIN 02528630 · 5 mg · extended release capsule

Limited Use, Reason for Use code 410 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 410 required
Write on scriptReason for Use code 410 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 410
Reason for Use code 410 For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Tacrolimus XR · DIN 02528630 Manufacturer: Sandoz Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-11-25 · brand SANDOZ TACROLIMUS XR · ATC L04AD02 TACROLIMUS · form Capsule (extended-release) · route Oral · ingredients TACROLIMUS 5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Tacrolimus XR: Formulary list price $7.82 per unit (the source does not state the unit; exact figure $7.8213). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528630)

Source record
DIN 02528630: Sandoz Tacrolimus XR Raw flags: sec12=Y, sec3=Y Item: 920000593; group id 967; item number 2298; lccId 00200; manufacturer id SDZ Source form: ER Cap; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $7.8213; ministry $7.8213 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528630 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101784
Interchangeable products
Advagraf · DIN 02296489 · $7.8213
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528630
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L04A, L04AD): coverage varies; not interchangeable

  • Cyclosporine (Neoral): general benefit
  • Azathioprine (Imuran): general benefit
  • Leflunomide (Arava): general benefit
  • Mycophenolate mofetil (CellCept): general benefit, limited Use 556
  • Mycophenolate (Myfortic): general benefit
  • Adalimumab (Hyrimoz): limited Use 600, 601, 602, 603, 604, 605, 606, 607, 609, 611, limited Use 600, 602, 603, 604, 605, 606, 607, 609, 633, 634

17 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

MYCOPHENOLATE MOFETIL

· 16 products · General benefit (14), Limited Use, codes 556 (2) · strengths: 250mg, 200mg/mL, 500mg · Cap, Pd for Oral Susp-175mL Pk, Tab

MYCOPHENOLATE SODIUM

· 8 products · General benefit · strengths: 180mg, 360mg · Ent Tab

FINASTERIDE

· 23 products · Off-Formulary Interchangeable, not an ODB benefit (8), Limited Use, codes 384, 385 (15) · strengths: 1mg, 5mg · Tab

LENALIDOMIDE

· 42 products · Limited Use, codes 630, 631, 632, 659, 741 · strengths: 2.5mg, 15mg, 20mg, 25mg, 5mg, 10mg · Cap

SIROLIMUS

· 2 products · Limited Use, codes 392 · strengths: 1mg/mL, 1mg · O/L, Tab

TERIFLUNOMIDE

· 10 products · Listed, not a benefit (1), Limited Use, codes 647 (9) · strengths: 14mg · Tab

USTEKINUMAB

· 17 products · Limited Use, codes 669, 670, 671, 672 (5), Limited Use, codes 669, 671, 672, 742 (4), Limited Use, codes 668, 669, 671, 672 (2), Limited Use, codes 669, 671, 672, 733 (3), Limited Use, codes 671, 672 (3) · strengths: 45mg/0.5mL, 90mg/1.0mL, 90mg/mL, 130mg/26mL, 5mg/mL · Inj Sol-0.5mL Pref Autoinj (Preservative-Free), Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.5mL Pref Syr Pk, Inj Sol-0.5mL Pref Syr Pk (Preservative-Free), Inj Sol-0.5mL Vial Pk, Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr Pk, Inj Sol-26mL Vial Pk, Inj Sol-26mL Vial Pk (Preservative-Free), Inj Sol-Vial Pk (Preservative-Free)

FINGOLIMOD

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.5mg · Cap

IVERMECTIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes:

Other drugs in the same formulary class (92:44 Immunosuppressive Agents) and how they are covered

Matched class: 92:44 Immunosuppressive Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:44 Immunosuppressive Agents

BARICITINIB

· 2 products · Limited Use, codes 615, 734 (1), Limited Use, codes 734 (1) · strengths: 2mg, 4mg · Tab

CLADRIBINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:44
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEFLUNOMIDE, PENICILLAMINE, SULFASALAZINE CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph SULFASALAZINE · General benefit It is especially useful for chronic administration. pms-SULFASALAZINE-E.C. is also indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed. PM: https://pdf.hres.ca/dpd_pm/00056638.PDF; date April 30, 2020; DIN 00598461; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS Transplantation Prograf® (tacrolimus) is indicated for: • prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. • treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants. Prograf is to be used concomitantly with adrenal corticosteroids and other immunosuppressive agents. The safety and efficacy of the use of Prograf with sirolimus has not been established. Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe Prograf (tacrolimus). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Rheumatoid Arthritis Prograf (tacrolimus immediate-release capsules, USP) is indicated for: • treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate. Prograf may be used as monotherapy or in combination with non-st… https://pdf.hres.ca/dpd_pm/00082912.PDF PM date: 2025-12-17 Source product: PROGRAF; DIN 02175983; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Protopic · DIN 02244149 Shortage status: discontinued (2025-04-15, reported by LEO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244149

Check this DIN again

Protopic · DIN 02244148 Shortage status: discontinued (2025-04-15, reported by LEO PHARMA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244148

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18